OC
NTGN

Oppenheimer & Co’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Oppenheimer & Co’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-31,127
Closed -$54K – 1347
2019
Q3 		$54K Buy
31,127
+1,023
+3% +$3.11K ﹤0.01% 1234
2019
Q2 		$143K Buy
30,104
+23
+0.1% +$129 ﹤0.01% 1235
2019
Q1 		$194K Buy
+30,081
New +$157K 0.01% 1231

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's NTGN Position: Q4 2019 in Review

Oppenheimer & Co sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2019, closing a stake of 31,127 shares — an estimated $54K sold.

Oppenheimer & Co first reported a position in NTGN in Q1 2019 and held it in 3 quarters. The position peaked at $194K in Q1 2019. 46 funds tracked by Wall St. Rank hold NTGN as of Q4 2019.

  • Oppenheimer & Co reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 31,127 Neon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $54K.
  • Oppenheimer & Co first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Oppenheimer & Co's Neon Therapeutics, Inc. Common Stock position peaked at $194K in Q1 2019.
  • 46 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Oppenheimer & Co's 13F filing for Q4 2019, filed 7 Feb 2020.